HitGen Inc. (SSE: 688222.SH), founded in 2012, is headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen is committed to building a world-class innovative biopharmaceutical enterprise and contributing to the better life and health of mankind. Engaged in the discovery and optimization of small molecules and nucleic acid drugs, HitGen dedicates itself to cultivating an internationally leading drug discovery and optimization system centered on four key technology platforms, including DNA-encoded library technology (including DEL design, synthesis and screening, and application expansion), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). It provides new molecular entities (NMEs) at different stages of research and development for the pharmaceutical industry, through its diversified business models including research and development services, out-licensing of projects at different R&D stages, and new drug launches in the long term, with an aim to address unmet clinical needs with innovative therapeutic solutions. As a leader in the field of DEL technology, HitGen has been committed to the development, application and improvement of DEL technology since its establishment. HitGen has approximately 20 in-house drug discovery projects at different stages of research and development, among which 4 have obtained IND approvals and entered into clinical trials. HitGen is in collaboration with pharmaceutical, biotech and chemical companies, foundations and research institutes in the Americas, Asia, Europe, Africa, and Oceania. For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com. For business development: bd@hitgen.com
View Top Employees from HitGen Inc.Website | http://www.hitgen.com |
Revenue | $35 million |
Employees | 79 (79 on RocketReach) |
Founded | 2012 |
Address | Floor 7-10, Building B3, Tianfu Life Science Park, Sichuan, CN |
Phone | +86 28 8519 7385 |
Technologies |
HTML,
ASP.NET,
YouTube
+3 more
(view full list)
|
Industry | Biotechnology, Biotechnology Research, Hit identification, Pharmaceuticals, Science and Engineering, Lead generation, Healthcare, Health Care, Chemical library synthesis, Medical, Compound library design, Early phase R&D, Affinity screening, Protein production and purification, DNA encoded libraries, Hit expansion libraries, Screening libraries, Focused libraries |
Web Rank | 5 Million |
Keywords | 先导药物, 先导, Dna Encoded Library Drug Discovery |
Looking for a particular HitGen Inc. employee's phone or email?
The HitGen Inc. annual revenue was $35 million in 2024.
Brian Moloney is the Chief Business Officer (CBO) of HitGen Inc..
79 people are employed at HitGen Inc..